Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Northwest Bioth Cmn (NWBO)

Northwest Bioth Cmn (NWBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 131,090
  • Shares Outstanding, K 601,330
  • Annual Sales, $ 410 K
  • Annual Income, $ -35,790 K
  • 60-Month Beta 1.51
  • Price/Sales 324.02
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.05
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/15/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2079 +7.94%
on 11/13/19
0.2345 -4.31%
on 11/13/19
-0.0006 (-0.27%)
since 11/12/19
3-Month
0.2020 +11.09%
on 11/08/19
0.2940 -23.67%
on 09/13/19
-0.0556 (-19.86%)
since 09/12/19
52-Week
0.1800 +24.67%
on 08/26/19
0.3500 -35.89%
on 03/14/19
-0.0736 (-24.70%)
since 12/12/18

Most Recent Stories

More News
Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has further expanded its senior...

NWBO : 0.2244 (+2.94%)
Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team

BETHESDA, Md. , Dec. 12, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...

NWBO : 0.2244 (+2.94%)
Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer...

NWBO : 0.2244 (+2.94%)
Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit

BETHESDA, Md. , Dec. 11, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...

NWBO : 0.2244 (+2.94%)
Patients Turn to Advanced Technology in Order to Combat Cancer

Over the past two decades, cancer-related deaths in the U.S. have declined significantly. As of 2015, the death rate for both men and women declined by 26% from its peak in 1991, according to the American...

ONPH : 0.0331 (unch)
INO : 2.71 (+2.65%)
REGN : 372.16 (-0.37%)
AVEO : 0.70 (unch)
SLS : 4.06 (-5.36%)
NWBO : 0.2244 (+2.94%)
NW Bio Moves Forward With SEC Settlement

Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement with...

NWBO : 0.2244 (+2.94%)
NW Bio Moves Forward With SEC Settlement

BETHESDA, Md. , Oct. 10, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today...

NWBO : 0.2244 (+2.94%)
NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations

BETHESDA, Md. , Sept. 4, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...

NWBO : 0.2244 (+2.94%)
NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has expanded its senior management...

NWBO : 0.2244 (+2.94%)
Highlights Of NW Bio's Program Update In The Industry Expert Theater Presentation At ASCO

NWBO : 0.2244 (+2.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NWBO with:

Key Turning Points

2nd Resistance Point 0.2340
1st Resistance Point 0.2292
Last Price 0.2244
1st Support Level 0.2148
2nd Support Level 0.2052

See More

52-Week High 0.3500
Fibonacci 61.8% 0.2851
Fibonacci 50% 0.2650
Fibonacci 38.2% 0.2449
Last Price 0.2244
52-Week Low 0.1800

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar